OncBioMune Pharmaceuticals Begins Trading Under Ticker OBMP

BATON ROUGE, LA--(Marketwired - September 29, 2015) - OncBioMune Pharmaceuticals, Inc. (the "Company") (OTC PINK: OBMP) announces today that subsequent to the Company's acquisition of Quint Media, Inc., the Financial Industry Regulatory Authority, Inc. (FINRA) has approved a change of the Company's stock ticker symbol. Effective today, OncBioMune's common shares will commence trading on the OTC Bulletin Board under the trading symbol "OBMP."

OncBioMune's lead product candidate, ProscaVax, is in clinical development as a novel immunotherapy vaccine for the treatment of prostate cancer and has been developed in part through multi-million dollar funding from the Navy Cancer Vaccine Program. ProscaVax utilizes tumor antigens combined with biological adjuvants to immunize patients as a monotherapy or combination therapy to boost the immune system to attack cancer cells in relapsed, refractory or patients at risk of prostate cancer progression. Administration of the vaccine to hundreds of patients has demonstrated low toxicity of OncBioMune's therapeutic cancer vaccines. A Phase 2 trial of ProscaVax for prostate cancer is currently being planned, with details of the trial expected to be released shortly.

"I am extremely pleased with the direction of our company following the acquisition and ticker change, as we are now exactly where we want to be from a clinical and fundamental perspective," commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. "We believe we have a very promising immuno-oncology vaccine candidate that can address a tremendous area of unmet medical need with respect to a new therapeutic for prostate cancer. The entry into the public markets is already generating new exposure that has been very well received. I greatly look forward to what is ahead of our company and its shareholders."

About OncBioMune Pharmaceuticals

OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary Vaccine Technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient. Our lead product, ProscaVax(r) is scheduled to commence a Phase 2 clinical study in early 2016. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceutical's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals' need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical's vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.